Abstract
CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Current Pediatric Reviews
Title: The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Volume: 4 Issue: 1
Author(s): Randi J. Hagerman, Susan M. Rivera and Paul J. Hagerman
Affiliation:
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Abstract: CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Export Options
About this article
Cite this article as:
Hagerman J. Randi, Rivera M. Susan and Hagerman J. Paul, The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments, Current Pediatric Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339608783565770
DOI https://dx.doi.org/10.2174/157339608783565770 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hydrogen/Deuterium Exchange-Mass Spectrometry: A Powerful Tool for Probing Protein Structure, Dynamics and Interactions
Current Medicinal Chemistry Alternative Gene Therapy Strategies for the Repair of Craniofacial Bone Defects
Current Gene Therapy Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design MicroRNAs in Arterial Hypertension
Current Topics in Medicinal Chemistry The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Short Peptide Modules for Enhancing Intestinal Barrier Function
Current Pharmaceutical Design A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and their Treatment Implications
Current Neuropharmacology Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Bright Light Delights: Effects of Daily Light Exposure on Emotions, Restactivity Cycles, Sleep and Melatonin Secretion in Severely Demented Patients
Current Alzheimer Research Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science Antiglucocorticoids, Neurogenesis and Depression
Mini-Reviews in Medicinal Chemistry Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Vascular effects of flavonoids
Current Medicinal Chemistry Regulation of the Metabolism of Polyunsaturated Fatty Acids and Butyrate in Colon Cancer Cells
Current Pharmaceutical Biotechnology